 | • レポートコード：D0804-14712 • 出版社/出版日：GlobalInfoResearch / 2020年7月21日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、127ページ • 納品方法：Eメール • 産業分類：医薬品・治療 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、アルファ1アンチトリプシン欠乏症治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。アルファ1アンチトリプシン欠乏症治療の種類別市場規模（増強療法、気管支拡張剤、コルチコステロイド、酸素療法）、用途別市場規模（病院、専門クリニック、薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Pfizer、GlaxoSmithKline、Grifols、Baxter、Kamada Ltd、AstraZeneca、Takeda、Boehringer Ingelheim、Teva Pharmaceutical Industries、CSL Behring、Baxalta、Chiesi Pharmaceuticals、LFB Biomedicaments、ProMetic Life Sciences、Arrowhead Research Corporation、Applied Genetic Technologies、Abeona Therapeutics、Curaxys、ProBioGen、Biogen ・地域別グローバル市場分析 2015年-2020年 ・アルファ1アンチトリプシン欠乏症治療の北米市場（アメリカ、カナダ、メキシコ） ・アルファ1アンチトリプシン欠乏症治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・アルファ1アンチトリプシン欠乏症治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・アルファ1アンチトリプシン欠乏症治療の南米市場（ブラジル、アルゼンチン） ・アルファ1アンチトリプシン欠乏症治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：増強療法、気管支拡張剤、コルチコステロイド、酸素療法 ・用途別分析：病院、専門クリニック、薬局 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The global Alpha 1 Antitrypsin Deficiency Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.9% in the forecast period of 2020 to 2025 and will expected to reach USD 1433 million by 2025, from USD 1184.2 million in 2019.
The Alpha 1 Antitrypsin Deficiency Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Alpha 1 Antitrypsin Deficiency Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Alpha 1 Antitrypsin Deficiency Treatment market has been segmented into:
Augmentation Therapy
Bronchodilators
Corticosteroids
Oxygen Therapy
By Application, Alpha 1 Antitrypsin Deficiency Treatment has been segmented into:
Hospitals
Specialty Clinics
Pharmacies
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Alpha 1 Antitrypsin Deficiency Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Alpha 1 Antitrypsin Deficiency Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Alpha 1 Antitrypsin Deficiency Treatment market.
The report offers in-depth assessment of the growth and other aspects of the Alpha 1 Antitrypsin Deficiency Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Alpha 1 Antitrypsin Deficiency Treatment Market Share Analysis
Alpha 1 Antitrypsin Deficiency Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Alpha 1 Antitrypsin Deficiency Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Alpha 1 Antitrypsin Deficiency Treatment sales, revenue and market share for each player covered in this report.
The major players covered in Alpha 1 Antitrypsin Deficiency Treatment are:
Pfizer
GlaxoSmithKline
Grifols
Baxter
Kamada Ltd
AstraZeneca
Takeda
Boehringer Ingelheim
Teva Pharmaceutical Industries
CSL Behring
Baxalta
Chiesi Pharmaceuticals
LFB Biomedicaments
ProMetic Life Sciences
Arrowhead Research Corporation
Applied Genetic Technologies
Abeona Therapeutics
Curaxys
ProBioGen
Biogen
Table of Contents
1 Alpha 1 Antitrypsin Deficiency Treatment Market Overview
1.1 Product Overview and Scope of Alpha 1 Antitrypsin Deficiency Treatment
1.2 Classification of Alpha 1 Antitrypsin Deficiency Treatment by Type
1.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Type in 2019
1.2.3 Augmentation Therapy
1.2.4 Bronchodilators
1.2.5 Corticosteroids
1.2.6 Oxygen Therapy
1.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market by Application
1.3.1 Overview: Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Pharmacies
1.4 Global Alpha 1 Antitrypsin Deficiency Treatment Market by Regions
1.4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Alpha 1 Antitrypsin Deficiency Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Alpha 1 Antitrypsin Deficiency Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Alpha 1 Antitrypsin Deficiency Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Alpha 1 Antitrypsin Deficiency Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Alpha 1 Antitrypsin Deficiency Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Alpha 1 Antitrypsin Deficiency Treatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 GlaxoSmithKline SWOT Analysis
2.2.4 GlaxoSmithKline Product and Services
2.2.5 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 Grifols
2.3.1 Grifols Details
2.3.2 Grifols Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Grifols SWOT Analysis
2.3.4 Grifols Product and Services
2.3.5 Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Baxter
2.4.1 Baxter Details
2.4.2 Baxter Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Baxter SWOT Analysis
2.4.4 Baxter Product and Services
2.4.5 Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 Kamada Ltd
2.5.1 Kamada Ltd Details
2.5.2 Kamada Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Kamada Ltd SWOT Analysis
2.5.4 Kamada Ltd Product and Services
2.5.5 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 AstraZeneca
2.6.1 AstraZeneca Details
2.6.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 AstraZeneca SWOT Analysis
2.6.4 AstraZeneca Product and Services
2.6.5 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.7 Takeda
2.7.1 Takeda Details
2.7.2 Takeda Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Takeda SWOT Analysis
2.7.4 Takeda Product and Services
2.7.5 Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.8 Boehringer Ingelheim
2.8.1 Boehringer Ingelheim Details
2.8.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Boehringer Ingelheim SWOT Analysis
2.8.4 Boehringer Ingelheim Product and Services
2.8.5 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.9 Teva Pharmaceutical Industries
2.9.1 Teva Pharmaceutical Industries Details
2.9.2 Teva Pharmaceutical Industries Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Teva Pharmaceutical Industries SWOT Analysis
2.9.4 Teva Pharmaceutical Industries Product and Services
2.9.5 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.10 CSL Behring
2.10.1 CSL Behring Details
2.10.2 CSL Behring Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 CSL Behring SWOT Analysis
2.10.4 CSL Behring Product and Services
2.10.5 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.11 Baxalta
2.11.1 Baxalta Details
2.11.2 Baxalta Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Baxalta SWOT Analysis
2.11.4 Baxalta Product and Services
2.11.5 Baxalta Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.12 Chiesi Pharmaceuticals
2.12.1 Chiesi Pharmaceuticals Details
2.12.2 Chiesi Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Chiesi Pharmaceuticals SWOT Analysis
2.12.4 Chiesi Pharmaceuticals Product and Services
2.12.5 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.13 LFB Biomedicaments
2.13.1 LFB Biomedicaments Details
2.13.2 LFB Biomedicaments Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 LFB Biomedicaments SWOT Analysis
2.13.4 LFB Biomedicaments Product and Services
2.13.5 LFB Biomedicaments Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.14 ProMetic Life Sciences
2.14.1 ProMetic Life Sciences Details
2.14.2 ProMetic Life Sciences Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 ProMetic Life Sciences SWOT Analysis
2.14.4 ProMetic Life Sciences Product and Services
2.14.5 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.15 Arrowhead Research Corporation
2.15.1 Arrowhead Research Corporation Details
2.15.2 Arrowhead Research Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Arrowhead Research Corporation SWOT Analysis
2.15.4 Arrowhead Research Corporation Product and Services
2.15.5 Arrowhead Research Corporation Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.16 Applied Genetic Technologies
2.16.1 Applied Genetic Technologies Details
2.16.2 Applied Genetic Technologies Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Applied Genetic Technologies SWOT Analysis
2.16.4 Applied Genetic Technologies Product and Services
2.16.5 Applied Genetic Technologies Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.17 Abeona Therapeutics
2.17.1 Abeona Therapeutics Details
2.17.2 Abeona Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Abeona Therapeutics SWOT Analysis
2.17.4 Abeona Therapeutics Product and Services
2.17.5 Abeona Therapeutics Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.18 Curaxys
2.18.1 Curaxys Details
2.18.2 Curaxys Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Curaxys SWOT Analysis
2.18.4 Curaxys Product and Services
2.18.3 Curaxys Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.19 ProBioGen
2.19.1 ProBioGen Details
2.19.2 ProBioGen Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 ProBioGen SWOT Analysis
2.19.4 ProBioGen Product and Services
2.19.5 ProBioGen Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.20 Biogen
2.20.1 Biogen Details
2.20.2 Biogen Major Business and Total Revenue (Financial Highlights) Analysis
2.20.3 Biogen SWOT Analysis
2.20.4 Biogen Product and Services
2.20.5 Biogen Alpha 1 Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share
3.2.2 Top 10 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Market Share by Regions
4.2 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
5 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries
5.1 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries (2015-2020)
5.2 USA Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
6 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries
6.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries (2015-2020)
6.2 Germany Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
6.4 France Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries
7.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries (2015-2020)
7.2 China Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
7.5 India Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
8 South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries
8.1 South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries (2015-2020)
8.2 Brazil Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Alpha 1 Antitrypsin Deficiency Treatment by Countries
9.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by Type (2019-2024)
10.3 Augmentation Therapy Revenue Growth Rate (2015-2025)
10.4 Bronchodilators Revenue Growth Rate (2015-2025)
10.5 Corticosteroids Revenue Growth Rate (2015-2025)
10.6 Oxygen Therapy Revenue Growth Rate (2015-2025)
11 Global Alpha 1 Antitrypsin Deficiency Treatment Market Segment by Application
11.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Application (2015-2020)
11.2 Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Specialty Clinics Revenue Growth (2015-2020)
11.5 Pharmacies Revenue Growth (2015-2020)
12 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecast (2021-2025)
12.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecast (2021-2025)
12.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by Regions (2021-2025)
12.3 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Forecast (2021-2025)
12.6 South America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Alpha 1 Antitrypsin Deficiency Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Pfizer Corporate Information, Location and Competitors
Table 6. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 7. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 8. Pfizer SWOT Analysis
Table 9. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 10. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. GlaxoSmithKline Corporate Information, Location and Competitors
Table 12. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 13. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2018-2019)
Table 14. GlaxoSmithKline SWOT Analysis
Table 15. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 16. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Grifols Corporate Information, Location and Competitors
Table 18. Grifols Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 19. Grifols Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 20. Grifols SWOT Analysis
Table 21. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 22. Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Baxter Corporate Information, Location and Competitors
Table 24. Baxter Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 25. Baxter Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 26. Baxter SWOT Analysis
Table 27. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 28. Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Kamada Ltd Corporate Information, Location and Competitors
Table 30. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 31. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 32. Kamada Ltd SWOT Analysis
Table 33. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 34. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. AstraZeneca Corporate Information, Location and Competitors
Table 36. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 37. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 38. AstraZeneca SWOT Analysis
Table 39. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 40. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Takeda Corporate Information, Location and Competitors
Table 42. Takeda Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 43. Takeda Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 44. Takeda SWOT Analysis
Table 45. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 46. Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Boehringer Ingelheim Corporate Information, Location and Competitors
Table 48. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 49. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 50. Boehringer Ingelheim SWOT Analysis
Table 51. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 52. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Teva Pharmaceutical Industries Corporate Information, Location and Competitors
Table 54. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 55. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 56. Teva Pharmaceutical Industries SWOT Analysis
Table 57. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 58. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. CSL Behring Corporate Information, Location and Competitors
Table 60. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 61. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 62. CSL Behring SWOT Analysis
Table 63. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 64. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Baxalta Corporate Information, Location and Competitors
Table 66. Baxalta Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 67. Baxalta Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 68. Baxalta SWOT Analysis
Table 69. Baxalta Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 70. Baxalta Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Chiesi Pharmaceuticals Corporate Information, Location and Competitors
Table 72. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 73. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 74. Chiesi Pharmaceuticals SWOT Analysis
Table 75. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 76. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. LFB Biomedicaments Corporate Information, Location and Competitors
Table 78. LFB Biomedicaments Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 79. LFB Biomedicaments Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 80. LFB Biomedicaments SWOT Analysis
Table 81. LFB Biomedicaments Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 82. LFB Biomedicaments Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. ProMetic Life Sciences Corporate Information, Location and Competitors
Table 84. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 85. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 86. ProMetic Life Sciences SWOT Analysis
Table 87. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 88. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 89. Arrowhead Research Corporation Corporate Information, Location and Competitors
Table 90. Arrowhead Research Corporation Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 91. Arrowhead Research Corporation Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 92. Arrowhead Research Corporation SWOT Analysis
Table 93. Arrowhead Research Corporation Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 94. Arrowhead Research Corporation Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 95. Applied Genetic Technologies Corporate Information, Location and Competitors
Table 96. Applied Genetic Technologies Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 97. Applied Genetic Technologies Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 98. Applied Genetic Technologies SWOT Analysis
Table 99. Applied Genetic Technologies Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 100. Applied Genetic Technologies Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 101. Abeona Therapeutics Corporate Information, Location and Competitors
Table 102. Abeona Therapeutics Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 103. Abeona Therapeutics Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 104. Abeona Therapeutics SWOT Analysis
Table 105. Abeona Therapeutics Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 106. Abeona Therapeutics Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 107. Curaxys Alpha 1 Antitrypsin Deficiency Treatment Type and Application
Table 108. Curaxys Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 109. Curaxys Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 110. Curaxys SWOT Analysis
Table 111. Curaxys Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 112. Curaxys Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 113. ProBioGen Corporate Information, Location and Competitors
Table 114. ProBioGen Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 115. ProBioGen Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 116. ProBioGen SWOT Analysis
Table 117. ProBioGen Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 118. ProBioGen Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 119. Biogen Corporate Information, Location and Competitors
Table 120. Biogen Alpha 1 Antitrypsin Deficiency Treatment Major Business
Table 121. Biogen Alpha 1 Antitrypsin Deficiency Treatment Total Revenue (USD Million) (2017-2018)
Table 122. Biogen SWOT Analysis
Table 123. Biogen Alpha 1 Antitrypsin Deficiency Treatment Product and Solutions
Table 124. Biogen Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 125. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) by Players (2015-2020)
Table 126. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Players (2015-2020)
Table 127. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) by Regions (2015-2020)
Table 128. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Regions (2015-2020)
Table 129. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries (2015-2020)
Table 130. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries (2015-2020)
Table 131. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) by Countries (2015-2020)
Table 132. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) by Countries (2015-2020)
Table 133. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Countries (2015-2020)
Table 134. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries (2015-2020)
Table 135. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) by Countries (2015-2020)
Table 136. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries (2015-2020)
Table 137. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) by Type (2015-2020)
Table 138. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Type (2015-2020)
Table 139. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Forecast by Type (2021-2025)
Table 140. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2015-2020)
Table 141. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Application (2015-2020)
Table 142. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Forecast by Application (2021-2025)
Table 143. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Alpha 1 Antitrypsin Deficiency Treatment Picture
Figure 2. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Type in 2019
Figure 3. Augmentation Therapy Picture
Figure 4. Bronchodilators Picture
Figure 5. Corticosteroids Picture
Figure 6. Oxygen Therapy Picture
Figure 7. Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Application in 2019
Figure 8. Hospitals Picture
Figure 9. Specialty Clinics Picture
Figure 10. Pharmacies Picture
Figure 11. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2015-2025)
Figure 12. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Players in 2019
Figure 19. Global Top 5 Players Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share in 2019
Figure 20. Global Top 10 Players Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share in 2019
Figure 21. Key Players Market Share Trend
Figure 22. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 23. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Regions (2015-2020)
Figure 24. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Regions in 2018
Figure 25. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 26. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 27. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 28. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 29. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 30. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries (2015-2020)
Figure 31. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries in 2019
Figure 32. USA Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 33. Canada Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 34. Mexico Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 35. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries (2015-2020)
Figure 36. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries in 2019
Figure 37. Germany Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 38. UK Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 39. France Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 40. Russia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 41. Italy Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries (2015-2020)
Figure 43. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries in 2019
Figure 44. China Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 45. Japan Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 46. Korea Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 47. India Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 48. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 49. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries (2015-2020)
Figure 50. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries in 2019
Figure 51. Brazil Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 52. Argentina Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 53. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries (2015-2020)
Figure 54. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Countries in 2019
Figure 55. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 56. UAE Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 57. Egypt Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 58. South Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2015-2020)
Figure 59. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Type (2015-2020)
Figure 60. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Type in 2019
Figure 61. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by Type (2021-2025)
Figure 62. Global Augmentation Therapy Revenue Growth Rate (2015-2020)
Figure 63. Global Bronchodilators Revenue Growth Rate (2015-2020)
Figure 64. Global Corticosteroids Revenue Growth Rate (2015-2020)
Figure 65. Global Oxygen Therapy Revenue Growth Rate (2015-2020)
Figure 66. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Application (2015-2020)
Figure 67. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Application in 2019
Figure 68. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by Application (2021-2025)
Figure 69. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 70. Global Specialty Clinics Revenue Growth Rate (2015-2020)
Figure 71. Global Pharmacies Revenue Growth Rate (2015-2020)
Figure 72. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 73. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 74. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share Forecast by Regions (2021-2025)
Figure 75. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Forecast (2021-2025)
Figure 76. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Forecast (2021-2025)
Figure 77. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Forecast (2021-2025)
Figure 78. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Forecast (2021-2025)
Figure 79. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Forecast (2021-2025)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
ACTH欠乏症治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The ACTH Deficiency Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizat…- ACTH欠乏症治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The ACTH Deficiency Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizat…
- ビオチニダーゼ欠乏症の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The Biotinidase Deficiency market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization…
- アルファマンノシドーシスの世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Alpha Mannosidosis market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 7.6% in the forecast period of 2020 to 2025 and will expected to reach USD 7 million by 2025, from USD 5 million in 2019. The Alpha Mannosidosis market r…
- アルファサラセミアの世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Alpha Thalassemia market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Alpha Thalassemia market re…